SGS Expands Stability Testing Capacity
PTSM: Pharmaceutical Technology Sourcing and Management
Expanded storage capacity at the SGS laboratory in Mississauga, Canada increases stability testing capabilities.
SGS announced on May 16, 2017 that it has expanded storage capacity at its laboratory in Mississauga, Canada, for the stability testing of new drug substances and products for regulatory compliance adding nearly 200 cubic meters, for overall storage of approximately 450 cubic meters.
The additional capacity is split between six new chambers, which cover four standard storage conditions: 2–8° C, minus 20 ° C, 30° C /65% RH, and 40° C /75% RH. The chambers use a validated dual redundant cooling system with switch-over capability to ensure zero excursion in the event of mechanical failure, and are supported by gas-powered backup generators in the event of a prolonged power outage.
SGS offers long-term drug stability and accelerated stability studies, shelf-life assessment, in-use studies, short-term temperature excursion studies, and forced degradation assessments according to ICH Q5C and ICH Q1B. At the company’s laboratory in Wavre, Belgium, a new stability chamber has been installed, adding 84 cubic meters of capacity, bringing the total capacity to over 330 cubic meters.
Source: SGS
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
